We are live on ! Find out more
ALXN

Alexion Pharmaceuticals
ALXN

Delisted

ALXN was delisted on the 20th of July, 2021.

Back to rankings

824 hedge funds and large institutions have $31.3B invested in Alexion Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 204 funds opening new positions, 241 increasing their positions, 284 reducing their positions, and 80 closing their positions.

New
Increased
Maintained
Reduced
Closed

156% more funds holding in top 10

Funds holding in top 10: 18 → 46 (+28)

155% more first-time investments, than exits

New positions opened: 204 | Existing positions closed: 80

38% more capital invested

Capital invested by funds: $22.6B → $31.3B (+$8.67B)

28% more call options, than puts

Call options by funds: $559M | Put options by funds: $436M

17% more funds holding

Funds holding: 707 → 824 (+117)

15% less repeat investments, than reductions

Existing positions increased: 241 | Existing positions reduced: 284

Holders
824
Holders Change
+117
Holders Change %
+16.55%
% of All Funds
14.58%
Holding in Top 10
46
Holding in Top 10 Change
+28
Holding in Top 10 Change %
+155.56%
% of All Funds
0.81%
New
204
Increased
241
Reduced
284
Closed
80
Calls
$559M
Puts
$436M
Net Calls
+$123M
Net Calls Change
+$163M

Top Buyers

1
PCM
Pentwater Capital Management
Florida
+$380M
2
FCM
Farallon Capital Management
California
+$289M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$271M
4
HI
HBK Investments
Texas
+$221M
5
Millennium Management
Millennium Management
New York
+$211M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$451M
2
Ameriprise
Ameriprise
Minnesota
-$353M
3
O
OrbiMed
New York
-$259M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$203M
5
AQR Capital Management
AQR Capital Management
Connecticut
-$194M
Name Holding Trade Value Shares
Change 		Change in
Stake
ST
726
Smithfield Trust
Pennsylvania
$29K +$3.73K +29 +19%
WWM
727
Wolff Wiese Magana
California
$29K +$23.5K +183 New
CIA
728
CSat Investment Advisory
Michigan
$28K -$555K -4,318 -96%
HI
729
Hudock Inc
Pennsylvania
$28K – – –
LC
730
Lindbrook Capital
California
$28K +$1.54K +12 +7%
BAM
731
Bellevue Asset Management
Washington
$27K – – –
LWM
732
Liberty Wealth Management
California
$26K -$1.41K -11 -6%
GRP
733
Global Retirement Partners
California
$24K -$6.04K -47 -23%
CCA
734
Catalyst Capital Advisors
New York
$24K +$19.8K +154 New
CCM
735
Covington Capital Management
California
$23K – – –
WLPWM
736
Walled Lake Planning & Wealth Management
Illinois
$23K – – –
FAM
737
Fred Alger Management
New York
$21K – – –
SL
738
Savior LLC
Massachusetts
$21K – – –
HNB
739
Huntington National Bank
Ohio
$21K +$7.58K +59 +80%
SLF
740
Sun Life Financial
Ontario, Canada
$20K -$514 -4 -3%
RIA
741
RPG Investment Advisory
California
$20K – – –
EWM
742
Endurance Wealth Management
Rhode Island
$19K – – –
WB
743
Webster Bank
Connecticut
$19K – – –
PFBT
744
Parkside Financial Bank & Trust
Missouri
$19K +$2.19K +17 +16%
FMII
745
Farmers & Merchants Investments Inc
Nebraska
$18K – – –
ST
746
Sageworth Trust
Pennsylvania
$18K – – –
PVH
747
Psagot Value Holdings
Israel
$17K – – –
CCA
748
Childress Capital Advisors
Texas
$17K +$14.1K +110 New
CFO
749
CVA Family Office
Colorado
$16K – – –
OIA
750
Optimum Investment Advisors
Illinois
$16K – – –
28 29
30
31 32

ALXN Hedge Fund Activity: Q4 2020 in Review

824 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q4 2020, worth a combined $31.3B — up 38% from $22.6B a quarter earlier.

Buyers outnumbered sellers: 204 funds opened new ALXN positions and 80 closed out — a net gain of 124 holders — while 241 added to existing stakes and 284 trimmed.

The largest buyer was Pentwater Capital Management, opening a new position worth an estimated $380M. The largest seller was Fidelity Investments, cutting an estimated $451M.

  • 824 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q4 2020, up from 707 in Q3 2020.
  • Funds reported $31.3B of Alexion Pharmaceuticals stock for Q4 2020, up 38% quarter-over-quarter.
  • 204 funds opened new Alexion Pharmaceuticals positions in Q4 2020 and 80 closed out, a net change of +124 holders.
  • The largest Alexion Pharmaceuticals buyer in Q4 2020 was Pentwater Capital Management, an estimated $380M added.
  • The largest Alexion Pharmaceuticals seller in Q4 2020 was Fidelity Investments, an estimated $451M sold.

Based on aggregated 13F filings for Q4 2020.